FDA holds drug makers to the strictest cGMP rules of any product category. Every batch must be made under validated processes, tested against approved specifications and released by an independent quality unit. JJCC Group builds and repairs those systems for Rx, OTC, API and biologics manufacturers, and for the brands that hire them.
Our specialized pharmaceutical consulting services provide expert guidance in contract manufacturing oversight, CDMO selection and management, biologics compliance, cGMP training, and FDA-ready quality assurance — helping drug manufacturers achieve regulatory excellence at every stage of product development.
Finished drug cGMP
21 CFR Parts 210 and 211
01/
Biologics
21 CFR Parts 600–680, plus Parts 210 and 211
02/
APIs
FD&C Act 501(a)(2)(B); ICH Q7 as FDA's recommendation
Trusted advisory relationships that evolve with your business
Deep technical knowledge of every subpart of 21 CFR Part 211
Decades of combined cGMP experience across pharmaceutical, biologics, and bioscience manufacturing
Proven track record supporting startups, mid-size manufacturers
Integrated service offerings covering QMS, validation, quality control, documentation, and training under one roof
Why choose us?
Why Partner With JJCC Group Consultants
years in regulatory affairs
0+
Satisfaction Rate
0%
Medical Partner
0+
Core Services
Our services include
We offer comprehensive support including cGMP facility setup, SOP development, process validation, audits, training, and regulatory compliance for pharmaceutical and biologic manufacturers.
Quality systems
under Part 211: quality unit, document control, deviations, change control, CAPA.
SOPs
master production records and batch records.
Process validation
across all three stages: design, qualification and continued verification.
Equipment and utility qualification
(IQ/OQ/PQ) and cleaning validation
Laboratory controls
method validation, stability programs, OOS and OOT investigations.
Rapid Response Remedy
for form 483 observations and Warning letter response
Robust CAPA Development
rooted in genuine root cause analysis
Mock FDA inspections
that mirror real agency expectations and methodology against 21 CFR 211 for drug and Biological products
Sustained audit readiness
programs that prepare your team for any regulatory visit
Comprehensive cGMP support for drug and biologics manufacturers
cGMP READINESS
Ready to strengthen your cGMP compliance?
Most drug 483s trace back to a few weak spots: investigations that stop too early, procedures not followed, lab controls and cleaning. We look there first, and we fix the system, not just the finding.